There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Densitas®, a global leader in artificial intelligence (AI) solutions for breast cancer screening, is pleased to announce a strategic collaboration with the ACR Learning Network, an initiative of the ...

Through seven distinct modules, the IAEA’s new mammography e-learning course provides health professionals to strengthen their theoretical and practical knowledge of this critical diagnostic tool for ...

Only about one in six individuals at high risk for lung cancer in the U.S. have heard of lung cancer screening or discussed ...

Results of a UCLA study recently published in the Journal of Breast Imaging demonstrates that Transpara's proven Breast AI ...

Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key ...

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report) today and set a price target ...

This interesting study presents valuable information on how human cytomegalovirus (HCMV) infection disrupts the activity of the TEAD1 transcription factor, leading to widespread chromatin alterations.

Investing in mammograms will save a high number of women currently dying from breast cancer due to late diagnosis, a new ...

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to ...

As dense breast tissue is often associated both with decreased mammographic sensitivity and increased individual risk, the ability of Transpara to detect these interval cancers earlier could ...